Last updated: 11/04/2018 08:35:51
Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures
EudraCT ID
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: A Multicenter, Double-blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-Release Adjunctive Therapy in Patients with Primary Generalized Tonic-Clonic Seizures
Trial description: This study is being conducted to compare the efficacy and safety of LAMICTAL (lamotrigine) extended-release with placebo in the treatment of Primary Generalized Tonic-Clonic (PGTC) seizures. LAMICTAL extended-release is an investigational drug. Placebo tablets look like LAMICTAL extended-release tablets but do not contain active medication. In this study, LAMICTAL extended-release or placebo tablets will be added to current seizure treatments.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:
Percent change from Baseline in weekly primary generalized tonic-clonic (PGTC) seizure frequency during the entire Double-Blind Treatment Phase
Timeframe: Baseline through end of Double-Blind Treatment Phase (up to Week 19)
Secondary outcomes:
Number of participants with >=25%, >=50%, >=75%, or 100% reduction in PGTC seizure frequency during the entire Double-Blind (DB)Treatment Phase (TP), the Escalation Phase, the Maintenance Phase, and the last 8 weeks of the Maintenance Phase
Timeframe: Entire DB Treatment Phase (Treatment Week 1 up to Week 19), Escalation Phase (Treatment Week 1 up to Week 7), Maintenance Phase (Treatment Week 8 up to Week 19), and the last 8 weeks of the Maintenance Phase (Treatment Week 12 up to Week 19)
Percent change from Baseline in PGTC seizure frequency during the Escalation Phase, the Maintenance Phase, and during the last 8 weeks of the Maintenance Phase of the Double-Blind Treatment Phase
Timeframe: Escalation Phase (Treatment Week 1 up to Week 7), Maintenance Phase (Treatment Week 8 up to Week 19), and the last 8 weeks of the Maintenance Phase (Week 12 up to Week 19)
Number of participants with the indicated time to >=50% reduction in seizure frequency in the Double-Blind Treatment Phase
Timeframe: Baseline through end of Double-Blind Treatment Phase (up to Week 19)
Change from Baseline in body weight at Week 19 of the Double-Blind Treatment Phase
Timeframe: Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)
Number of participants with improved clinical status on the Investigator’s Global Assessment in the Double-Blind Treatment Phase
Timeframe: Week 19 (or last on-study assessment in Double-Blind Treatment Phase)
Number of participants with improved satisfaction with seizure control on the Subject Satisfaction Questionnaire in the Double-Blind Treatment Phase
Timeframe: Week 19 (or last on-study assessment in Double-Blind Treatment Phase)
Percent change from Baseline in weekly PGTC seizure frequency during the entire Continuation Phase (CP), the Transition Phase, the Open-Label Phase, and the last 8 weeks of the Open-Label Phase
Timeframe: Entire CP (CP Week 1 up to Week 52), the Transition Phase (CP Week 1 up to Week 7), the Open-Label Phase (CP Week 8 up to Week 52), and the last 8 weeks of the Open-Label Phase (CP Week 45 up to Week 52)
Number of participants with >=25%, >=50%, >=75%, or 100% reduction or >=50% increase from Baseline in weekly PGTC seizure frequency for the entire Continuation Phase, the Transition Phase, the Open-Label (OL) Phase, and the last 8 weeks of the OL Phase.
Timeframe: Entire CP (CP Week 1 up to Week 52), the Transition Phase (CP Week 1 up to Week 7), the Open-Label Phase (CP Week 8 up to Week 52), and the last 8 weeks of the Open-Label Phase (CP Week 45 up to Week 52)
Mean Change from Baseline in the Profile of Mood State (POMS) Mood Disturbance Total Score at Week 19 of the Double-Blind Treatment Phase
Timeframe: Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)
Mean Change from Baseline in the Center for Epidemiological Studies-Depression Scale (CES-D) Total Score at Week 19 of the Double-Blind Treatment Phase
Timeframe: Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)
Mean Change from Baseline in the Neurological Disorders Depression Inventory-Epilepsy (NDDI-E) 6-Item Total Score at Week 19 of the Double-Blind Treatment Phase
Timeframe: Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)
Mean Change from Baseline in the Quality of Life in Epilepsy-31-P (QOLIE-31P) Overall Score at Week 19 of the Double-Blind Treatment Phase
Timeframe: Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)
Mean Change from Baseline in the Adverse Experience Profile (AEP) Total Score at Week 19 of the Double-Blind Treatment Phase
Timeframe: Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)
Mean Change from Baseline in the Seizure Severity Questionnaire (SSQ) Global Bother Score at Week 19 Double-Blind Treatment Phase
Timeframe: Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)
Mean Change from Baseline in the Epworth Sleepiness Scale (ESS) 8-Item Total Score at Week 19 of the Double-Blind Treatment Phase
Timeframe: Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)
Serum Concentrations and Population (POP) Pharmacokinetic Parameters for Lamotrigine
Timeframe: Blood samples drawn at Treatment Weeks 11, 15, and 19 (or last on-study measurement in Double-Blind Treatment Phase)
Interventions:
Drug: lamotrigine (LAMICTAL) extended-release
Drug: Placebo
Enrollment:
153
Observational study model:
Not applicable
Primary completion date:
2008-28-07
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Epilepsy, Tonic-Clonic
Product
lamotrigine
Collaborators
Not applicable
Study date(s)
December 2004 to July 2008
Type
Interventional
Phase
3
Participation criteria
Sex
Female & Male
Age
13+ years
Accepts healthy volunteers
No
- Is ≥13 years of age (male or female).
- Has a confident diagnosis of epilepsy with PGTC seizures for more than 24 weeks prior to the Baseline Phase.
- Has a history of partial seizures or interictal expression of partial seizures as evidenced by EEG NOTE: EEG may be historical or prospective.
- Has had status epilepticus within the 24 weeks prior to, or during, the Baseline Phase.
Inclusion and exclusion criteria
Inclusion criteria:
- Is ≥13 years of age (male or female).
- Has a confident diagnosis of epilepsy with PGTC seizures for more than 24 weeks prior to the Baseline Phase.
- Has electroencephalogram (EEG) evidence of either spike-and-wave discharges consistent with PGTC, or at least 2 EEGs with no indication of focal abnormalities. The EEG may be historical or prospective. Investigators may use a historical EEG as long as there is appropriate documentation.
- Has a documented history of PGTC seizures with or without other generalized seizure type(s) with no focal onset, and at least 1 PGTC seizure during the eight consecutive weeks (i.e., 56 consecutive days) prior to starting the 8-week Baseline Phase.
- Has at least 3 PGTC seizures occurring anytime during an 8-week (i.e., 56 days) prospective Baseline Phase. ·NOTE: When a historical baseline is used, the same time period cannot count for documentation of inclusion criteria 4 and 5. Additionally, innumerable seizure activity will not count towards the number of seizures required for randomization. ·NOTE: With authorization from GSK, a maximum of four weeks (i.e., 28 days) of historical seizure data may replace up to four weeks (i.e., 28 days) of the prospective Baseline Phase for subjects providing reliable documentation of the following: a.complete daily seizure diary that includes the number of seizures experienced each day along with the exact classification of each seizure type for consecutive days prior to the prospective Baseline Phase b.stability of prescribed dosages of background antiepileptic drugs (AEDs) c.compliance with background AEDs. ·All subjects permitted to use historical seizure data must complete a minimum of four weeks (i.e., 28 days) of the prospective Baseline Phase. The historical Baseline Phase and the prospective Baseline Phase must equal 56 consecutive days.
- Is currently treated with a stable regimen of one or two AED(s) for at least four weeks prior to starting the Baseline Phase (historical or prospective). ·NOTE: Benzodiazepines used chronically will be considered to be concurrent AEDs. ·NOTE: Subjects with surgically implanted vagal nerve stimulators (VNS) will be allowed to enter the study provided that all of the following conditions are met: a.VNS has been in place for at least 24 weeks prior to the Baseline Phase. b.The settings must remain the same for at least 28 days prior to the Baseline Phase. c.The settings must remain the same during the Baseline, Escalation, Maintenance and Transition Phases. d.The battery is expected to last for the duration of the study. e.VNS is counted as a "concurrent AED."
- Is able and willing to maintain an accurate and complete daily written seizure diary, or has a parent/caregiver who is able and willing to maintain an accurate and complete daily written seizure diary for the entire duration of the study.
- Is able to comply with dosing of study drugs, background AEDs and all study procedures.
- Has given written informed consent, or has a parent/legally authorized representative who has given written informed consent, prior to the performance of any study assessments.
- If female, and of childbearing potential, must be using an acceptable form of birth control, to include one of the following: a.Complete abstinence from intercourse for two weeks before exposure to the study drug, throughout the clinical trial, and for a period after the trial to account for elimination of the drug (a minimum of 3 weeks). b.Consistent and correct use of one of the following methods of birth control: ·Male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for that female subject ·Implants of levonorgestrel ·Injectable progestogen ·Oral contraceptive (either combined, with at least 50mcg estrogen for women on enzyme-induced AEDs, or progestogen only) ·Any intrauterine device (IUD) with a documented failure rate of less than 1% per year ·Double barrier method consisting of spermicide plus a mechanical barrier (e.g., spermicide plus a male condom or a female diaphragm). ·NOTE: Women who have had a hysterectomy, tubal ligation, or are post-menopausal are considered to be of non-childbearing potential.
Exclusion criteria:
- Has a history of partial seizures or interictal expression of partial seizures as evidenced by EEG NOTE: EEG may be historical or prospective.
- Has had status epilepticus within the 24 weeks prior to, or during, the Baseline Phase.
- Is taking three or more background AEDs chronically.
- Has Lennox-Gastaut syndrome.
- Is currently using or has previously used lamotrigine.
- Is currently taking felbamate.
- Is abusing alcohol and/or other substance(s).
- Has taken an investigational drug within the previous 30 days or plans to take an investigational drug anytime during the study.
- Is receiving chronic treatment with any medication that could influence seizure control. NOTE: Use of benzodiazepines is allowed.
- Is currently following the ketogenic diet.
- Is planning surgery to control seizures during the study.
- Is suffering from acute or progressive neurological disease, severe psychiatric disease, or severe mental abnormality that are likely to interfere with the objectives of the study.
- Has any clinically significant cardiac, renal, hepatic condition, or a condition that affects the absorption, distribution, metabolism or excretion of drugs.
- Is pregnant, breastfeeding, or planning to become pregnant during the study or within the three weeks after the last dose of study drug.
Trial location(s)
Location
GSK Investigational Site
San Juan, Puerto Rico, Puerto Rico, 00918
Status
Terminated/Withdrawn
Location
GSK Investigational Site
San German, Puerto Rico, Puerto Rico, 00683
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Santiago, Región Metro De Santiago, Chile
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Galveston, Texas, United States, 77555
Status
Terminated/Withdrawn
Location
GSK Investigational Site
New York, New York, United States, 10016
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Hollywood, Florida, United States, 33021
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Hamburg, Hamburg, Germany, 22083
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Las Vegas, Nevada, United States, 89106
Status
Study Complete
Location
GSK Investigational Site
Louisville, Kentucky, United States, 40202
Status
Study Complete
Location
GSK Investigational Site
Anniston, Alabama, United States, 36207
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Phoenix, Arizona, United States, 85006
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Chicago, Illinois, United States, 60612
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Kansas City, Missouri, United States, 64111
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Magdeburg, Sachsen-Anhalt, Germany, 39104
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Singen, Baden-Wuerttemberg, Germany, 78224
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Halle, Sachsen-Anhalt, Germany, 06118
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Essen, Nordrhein-Westfalen, Germany, 45122
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Jena, Thueringen, Germany, 07743
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Sepuldeva, California, United States, 91343
Status
Study Complete
Location
GSK Investigational Site
Tuscaloosa, Alabama, United States, 35406
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Moenchengladbach, Nordrhein-Westfalen, Germany, 41061
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Campinas, São Paulo, Brazil, 13083-970
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Edison, New Jersey, United States, 08818
Status
Study Complete
Location
GSK Investigational Site
Crestview Hills, Kentucky, United States, 41017
Status
Study Complete
Location
GSK Investigational Site
Birmingham, Alabama, United States, 35294-0021
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Maitland, Florida, United States, 32751
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Leipzig, Sachsen, Germany, 04157
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Atlanta, Georgia, United States, 30342
Status
Study Complete
Location
GSK Investigational Site
Marietta, Georgia, United States, 30060
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Des Moines, Iowa, United States, 50309-1426
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Unterhaching, Bayern, Germany, 82008
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Argentina, C1221ADC
Status
Study Complete
Location
GSK Investigational Site
Oklahoma City, Oklahoma, United States, 73112
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Wichita Falls, Texas, United States, 76301
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Bochum, Nordrhein-Westfalen, Germany, 44795
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Osnabrueck, Niedersachsen, Germany, 49074
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Chesterfield, Missouri, United States, 63017
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Koethen, Sachsen-Anhalt, Germany, 06366
Status
Study Complete
Location
GSK Investigational Site
Los Angeles, California, United States, 90073
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Bernau, Brandenburg, Germany, 16321
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Traverse City, Michigan, United States, 49684
Status
Study Complete
Location
GSK Investigational Site
Leipzig, Sachsen, Germany, 04105
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Detroit, Michigan, United States, 48202
Status
Study Complete
Location
GSK Investigational Site
Hyderabad, Andhra Pradesh, India, 500482
Status
Study Complete
Location
GSK Investigational Site
Goettingen, Niedersachsen, Germany, 37075
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Minneapolis, Minnesota, United States, 55455
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Santa Monica, California, United States, 90404
Status
Study Complete
Location
GSK Investigational Site
Straubing, Bayern, Germany, 94315
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Ciudad Autónoma de Buenos Aires, Argentina, 1425
Status
Study Complete
Location
GSK Investigational Site
Limburgerhof, Rheinland-Pfalz, Germany, 67117
Status
Study Complete
Location
GSK Investigational Site
Scottsdale, Arizona, United States, 85259
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Bernburg, Sachsen-Anhalt, Germany, 06406
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Naumburg, Sachsen-Anhalt, Germany, 06618
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Oklahoma City, Oklahoma, United States, 73104
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Madison, Wisconsin, United States, 53715
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19140
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Boston, Massachusetts, United States, 02118
Status
Study Complete
Location
GSK Investigational Site
Koeln, Nordrhein-Westfalen, Germany, 50767
Status
Study Complete
Location
GSK Investigational Site
Germantown, Tennessee, United States, 38138
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Bochum, Nordrhein-Westfalen, Germany, 44892
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Columbus, Ohio, United States, 43210-1250
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Wuerzburg, Bayern, Germany, 97070
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Hattingen, Nordrhein-Westfalen, Germany, 45525
Status
Study Complete
Location
GSK Investigational Site
Los Angeles, California, United States, 90033
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Washington, District of Columbia, United States, 20037
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Kiel, Schleswig-Holstein, Germany, 24105
Status
Study Complete
Location
GSK Investigational Site
Little Rock, Arkansas, United States, 72205
Status
Study Complete
Location
GSK Investigational Site
Neuoetting, Bayern, Germany, 84524
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Bueckeburg, Niedersachsen, Germany, 31675
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Magdeburg, Sachsen-Anhalt, Germany, 39124
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Grand Rapids, Michigan, United States, 49525
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Frankfurt, Hessen, Germany, 60594
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Capital Federal, Buenos Aires, Argentina, 1181
Status
Study Complete
Location
GSK Investigational Site
Essen, Nordrhein-Westfalen, Germany, 45138
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Amherst, New York, United States, 14226
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Springfield, Illinois, United States, 62702
Status
Study Complete
Location
GSK Investigational Site
Hamburg, Hamburg, Germany, 22527
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Hamburg, Hamburg, Germany, 21029
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Salt Lake City, Utah, United States, 84107
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Asheville, North Carolina, United States, 28801
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Richmond, Virginia, United States, 23220
Status
Study Complete
Location
GSK Investigational Site
Savannah, Georgia, United States, 31405
Status
Study Complete
Location
GSK Investigational Site
Hamburg, Hamburg, Germany, 22523
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Ulm, Baden-Wuerttemberg, Germany, 89073
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Muenster, Nordrhein-Westfalen, Germany, 48149
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19107
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Newport Beach, California, United States, 92660
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Bad Homburg, Hessen, Germany, 61348
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Phoenix, Arizona, United States, 85013
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Augusta, Georgia, United States, 30912-3200
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Milwaukee, Wisconsin, United States, 53215
Status
Terminated/Withdrawn
Location
GSK Investigational Site
San Antonio, Texas, United States, 78258
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Burlington, Vermont, United States, 05401
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Ludwigsfelde, Brandenburg, Germany, 14974
Status
Terminated/Withdrawn
Location
GSK Investigational Site
São Paulo, São Paulo, Brazil, 05403-900
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Hamburg, Hamburg, Germany, 20249
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Wismar, Mecklenburg-Vorpommern, Germany, 23966
Status
Terminated/Withdrawn
Location
GSK Investigational Site
San Juan, Puerto Rico, Puerto Rico, 00936
Status
Terminated/Withdrawn
Location
GSK Investigational Site
West Orange, New Jersey, United States, 07052
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Tucson, Arizona, United States, 85712
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Muenchen, Bayern, Germany, 80331
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Greenville, North Carolina, United States, 27834
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Suwanee, Georgia, United States, 30024
Status
Study Complete
Location
GSK Investigational Site
Northport, Alabama, United States, 35476
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Raleigh, North Carolina, United States, 27607
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Flossmoor, Illinois, United States, 60422
Status
Study Complete
Location
GSK Investigational Site
Lafayette, Louisiana, United States, 70503
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Minneapolis, Minnesota, United States, 55422
Status
Study Complete
Location
GSK Investigational Site
Baesweiler, Nordrhein-Westfalen, Germany, 52499
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Wismar, Mecklenburg-Vorpommern, Germany, 23970
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15215
Status
Terminated/Withdrawn
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2008-28-07
Actual study completion date
2008-28-07
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website